Valproic acid: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Valproic Acid/Sodium Valproate (Depakote) |FDA_approval=Yes (for epilepsy) |used_for=Investigational use in glioblastoma for its HDAC inhibition properties |clinical_trial_phase=Retrospective studies and a prospective phase II trial |common_side_effects=Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity |OS_without=Median survival with enzyme-inducing anticonvulsants:...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 10: | Line 10: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment. | |notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment. | ||
| | |treatment_category=Repurposed Drugs | ||
|links= | |links= | ||
|toxicity_level=3 | |||
|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level. | |||
}} | }} | ||
Latest revision as of 10:25, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Valproic Acid/Sodium Valproate (Depakote) |
| FDA Approval | Yes (for epilepsy) |
| Used for | Investigational use in glioblastoma for its HDAC inhibition properties |
| Clinical Trial Phase | Retrospective studies and a prospective phase II trial |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity |
| OS without | Median survival with enzyme-inducing anticonvulsants: 11 months |
| OS with | Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months |
| PFS without | Not specified |
| PFS with | Prospective study shows median PFS of 10.5 months |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 3 |
| Toxicity Explanation | Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level. |
Notes: Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.
From Ben Williams Book: Not specified
Loading comments...
